Skip to main content

Table 1 Preoperative clinicopathologic Data of Patients with CHC Who received or not postoperative TACE

From: Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis

Variable

Before Propensity Matching

After Propensity Matching

Without TACE (n = 184)

Postoperative TACE (n = 46)

P

Without TACE (n = 46)

Postoperative TACE (n = 46)

P

Sex

  

0.172

  

> 0.99

 Men

134

38

 

38

38

 

 Women

50

8

 

8

8

 

Mean age (y)

52.3 ± 12.1

52 ± 10.7

0.326

53.4 ± 11.6

52 ± 10.7

0.834

HBsAg

  

> 0.99

  

0.810

 Positive

136

34

 

35

34

 

 Negative

48

12

 

11

12

 

HBcAb

  

0.666

  

0.231

 Positive

153

9

 

42

9

 

 Negative

31

37

 

4

37

 

HCV antibody

  

> 0.99

  

> 0.99

 Positive

4

1

 

1

1

 

 Negative

180

45

 

45

45

 

Median AFP, ng/mL

24.7 (1–80,000)

96 (1.8–46,897)

0.006

21.3 (1–30,728)

96 (1.8–46,897)

0.002

Median CEA, μg/mL

2.5 (0–274)

2.1 (0.5–70.5)

0.364

2.7 (0.1–112.4)

2.1 (0.5–70.5)

0.423

Median CA19–9, U/ml

28.1 (0–4370)

19.4 (0.2–300.1)

0.029

22 (0.5–4062.5)

19.4 (0.2–300.1)

0.023

Median bilirubin, μmol/L

11.8 (1.7–314.8)

12.9 (5.7–156.5)

< 0.001

13.7 (2.4–169.3)

12.9 (5.7–156.5)

0.664

Median albumin, g/L

41 (26–55)

42 (35–66)

0.397

41 (30–48)

42 (35–66)

0.556

Median ALT, U/L

28 (5–484)

31 (5–104)

0.094

26 (11–484)

31 (5–104)

0.109

Median ALP, IU/L

89.5 (22–1413)

88.5 (46–184)

0.477

92 (25–331)

88.5 (46–184)

0.599

Median GGT, U/L

59 (3.6–1632)

80 (18–490)

0.923

75.5 (10–658)

80 (18–490)

0.273

Median platelets, 103/μL

13.7 (2.2–47.6)

16 (3.9–46.1)

0.319

15.3 (5.3–24.7)

16 (3.9–46.1)

0.171

Median prothrombin time, s

11.8 (9–17.6)

12 (10.2–13.8)

0.941

12 (10.2–14.6)

12 (10.2–13.8)

0.903

Median INR

1 (0.5–1.5)

1 (0.8–1.2)

0.227

1 (0.5–1.2)

1 (0.8–1.2)

0.065

Median tumour size, cm

5 (1–24)

7.3 (1.5–17)

0.626

6 (1.5–22)

7.3 (1.5–17)

0.384

Median tumour nodularities

1 (1–10)

1 (1–5)

0.140

1 (1–6)

1 (1–5)

0.648

Median blood loss, ml

200 (30–3500)

200 (10–2500)

0.182

200 (50–1800)

200 (10–2500)

0.480

Mean occlusion, min

6.8 ± 8.6

10 ± 1.6

0.044

5.4 ± 1.1

10 ± 1.6

0.090

Macrovascular invasion

  

0.041

  

> 0.99

 Positive

11

7

 

7

7

 

 Negative

173

39

 

39

39

 

Microvascular invasion

  

0.689

  

0.607

 Positive

39

11

 

8

11

 

 Negative

145

35

 

38

35

 

Lymphoid metastasis

  

0.840

  

> 0.99

 Positive

22

6

 

6

6

 

 Negative

162

40

 

40

40

 

Extrahepatic metastasis

  

0.719

  

0.646

 Positive

6

2

 

3

2

 

 Negative

178

44

 

43

44

 

Postrecurrent therapy

  

0.451

  

0.583

 Resection

2

1

 

1

1

 

 TACE

27

6

 

10

6

 

 Regional therapy

4

1

 

1

1

 

 Chemothearpy

66

14

 

11

14

 

 Selective internal radiation therapy

5

2

 

1

2

 

 Stereotactic body radiation

12

5

 

3

5

 

 Best supportive care

58

17

 

19

17

 
  1. Data are numbers of patients. Data in parentheses are range. Mean data are±standard deviation. Regional therapy: Radiofrequency ablation and percutaneous ethanol injection
  2. HBsAg hepatitis B surface antigen, HBcAb hepatitis B core antibody, HCV hepatitis C virus, AFP α-fetoprotein, CEA carcino-embryonic antigen, CA19–9 carbohydrate 19–9, INR International normalized ratio, ALT alanine aminotransferase, GGT γ-glutamyl transpeptidase, ALP alkaline phosphatase, MVI microvascular vascular invasion
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us